Who makes Urinaru gonadotropin?

Urinaru gonadotropin is developed by Cairo University.

What development phase is Urinaru gonadotropin in?

Urinaru gonadotropin is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Urinaru gonadotropin

Cairo University · FDA-approved active Small molecule Quality 2/100

Urinaru gonadotropin, marketed by Cairo University, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a unique mechanism of action that may offer a competitive edge. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Urinaru gonadotropin
Sponsor	Cairo University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Urinaru gonadotropin CI brief — competitive landscape report
Urinaru gonadotropin updates RSS · CI watch RSS
Cairo University portfolio CI